|
1
|
Krajicek BJ, Limper AH and Thomas CF Jr:
Advances in the biology, pathogenesis and identification of
Pneumocystis pneumonia. Curr Opin Pulm Med. 14:228–234.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lane BR, Ast JC, Hossler PA, et al:
Dihydropteroate synthase polymorphisms in Pneumocystis
carinii. J Infect Dis. 175:482–485. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kazanjian P, Locke AB, Hossler PA, et al:
Pneumocystis carinii mutations associated with sulfa and
sulfone prophylaxis failures in AIDS patients. AIDS. 12:873–878.
1998. View Article : Google Scholar
|
|
4
|
Riebold D, Fritzsche C, Lademann M, Bier A
and Reisinger EC: Pneumocystis jiroveci dihydropteroate
synthase gene mutations at codon 171 but not at codons 55 or 57
detected in Germany. Clin Infect Dis. 42:582–583. 2006. View Article : Google Scholar
|
|
5
|
Helweg-Larsen J, Benfield TL, Eugen-Olsen
J, Lundgren JD and Lundgren B: Effects of mutations in
Pneumocystis carinii dihydropteroate synthase gene on
outcome of AIDS-associated P. carinii pneumonia. Lancet.
354:1347–1351. 1999.
|
|
6
|
Kazanjian PH, Fisk D, Armstrong W, et al:
Increase in prevalence of Pneumocystis carinii mutations in
patients with AIDS and P. carinii pneumonia, in the United
States and China. J Infect Dis. 189:1684–1687. 2004.PubMed/NCBI
|
|
7
|
Li K, He A, Cai WP, et al: Absence of
Pneumocystis jirovecii dihydropteroate synthase gene
mutations among samples from a group of AIDS patients in China.
Scand J Infect Dis. 41:152–154. 2009.
|
|
8
|
Montes-Cano MA, de la Horra C, Martin-Juan
J, et al: Pneumocystis jiroveci genotypes in the Spanish
population. Clin Infect Dis. 39:123–128. 2004. View Article : Google Scholar
|
|
9
|
Huang L, Welsh DA, Miller RF, et al:
Pneumocystis jirovecii dihydropteroate synthase gene
mutations and human immunodeficiency virus-associated
Pneumocystis pneumonia. J Eukaryot Microbiol. 53(Suppl 1):
S114–S116. 2006. View Article : Google Scholar
|
|
10
|
Tyagi AK, Mirdha BR, Luthra K, et al:
Dihydropteroate synthase (DHPS) gene mutation study in HIV-infected
Indian patients with Pneumocystis jirovecii pneumonia. J
Infect Dev Ctries. 4:761–766. 2010.PubMed/NCBI
|
|
11
|
Dini L, du Plessis M, Frean J and
Fernandez V: High prevalence of dihydropteroate synthase mutations
in Pneumocystis jirovecii isolated from patients with
Pneumocystis pneumonia in South Africa. J Clin Microbiol.
48:2016–2021. 2010.PubMed/NCBI
|
|
12
|
Brown PD, Freeman A and Foxman B:
Prevalence and predictors of trimethoprim-sulfamethoxazole
resistance among uropathogenic Escherichia coli isolates in
Michigan. Clin Infect Dis. 34:1061–1066. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walker DJ and Meshnick SR: Drug resistance
in Pneumocystis carinii: an emerging problem. Drug Resist
Updat. 1:201–204. 1998.
|
|
14
|
Edman JC, Edman U, Cao M, Lundgren B,
Kovacs JA and Santi DV: Isolation and expression of the
Pneumocystis carinii dihydrofolate reductase gene. Proc Natl
Acad Sci USA. 86:8625–8629. 1989.PubMed/NCBI
|
|
15
|
Lane B, Hossler P, Bartlett M, et al:
Sulfa resistance in mouse-derived Pneumocystis carinii. J
Eukaryot Microbiol. 43:39S1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Crothers K, Atzori C, et al:
Dihydropteroate synthase gene mutations in Pneumocystis and
sulfa resistance. Emerg Infect Dis. 10:1721–1728. 2004. View Article : Google Scholar
|
|
17
|
Beard CB, Carter JL, Keely SP, et al:
Genetic variation in Pneumocystis carinii isolates from
different geographic regions: implications for transmission. Emerg
Infect Dis. 6:265–272. 2000.
|
|
18
|
Kazanjian P, Armstrong W, Hossler PA, et
al: Pneumocystis carinii mutations are associated with
duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
J Infect Dis. 182:551–557. 2000. View
Article : Google Scholar
|
|
19
|
Takahashi T, Hosoya N, Endo T, et al:
Relationship between mutations in dihydropteroate synthase of
Pneumocystis carinii f. sp hominis isolates in Japan
and resistance to sulfonamide therapy. J Clin Microbiol.
38:3161–3164. 2000.PubMed/NCBI
|
|
20
|
van Hal SJ, Gilgado F, Doyle T, et al:
Clinical significance and phylogenetic relationship of novel
Australian Pneumocystis jirovecii genotypes. J Clin
Microbiol. 47:1818–1823. 2009.PubMed/NCBI
|
|
21
|
Thomas CF Jr and Limper AH: Current
insights into the biology and pathogenesis of Pneumocystis
pneumonia. Nat Rev Microbiol. 5:298–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Boer MG, Gelinck LB, van Zelst BD, et
al: β-D-glucan and S-adenosylmethionine serum levels for the
diagnosis of Pneumocystis pneumonia in HIV-negative
patients: a prospective study. J Infect. 62:93–100. 2011.
|
|
23
|
Vogel MN, Weissgerber P, Goeppert B, et
al: Accuracy of serum LDH elevation for the diagnosis of
Pneumocystis jiroveci pneumonia. Swiss Med Wkly.
141:w131842011.PubMed/NCBI
|
|
24
|
Held J, Koch MS, Reischl U, Danner T and
Serr A: Serum (1→3)-β-D-glucan measurement as an early indicator of
Pneumocystis jirovecii pneumonia and evaluation of its
prognostic value. Clin Microbiol Infect. 17:595–602. 2011.
|
|
25
|
Limper AH, Offord KP, Smith TF and Martin
WJ II: Pneumocystis carinii pneumonia. Differences in lung
parasite number and inflammation in patients with and without AIDS.
Am Rev Respir Dis. 140:1204–1209. 1989. View Article : Google Scholar
|
|
26
|
Azoulay E, Bergeron A, Chevret S, Bele N,
Schlemmer B and Menotti J: Polymerase chain reaction for diagnosing
Pneumocystis pneumonia in non-HIV immunocompromised patients
with pulmonary infiltrates. Chest. 135:655–661. 2009.
|
|
27
|
Wang JC, Huang MJ, A YJ, et al: Screening
Pneumocystis carinii pneumonia in non-HIV-infected
immunocompromised patients using polymerase chain reaction. Diagn
Microbiol Infect Dis. 64:396–401. 2009.
|
|
28
|
Maskell NA, Waine DJ, Lindley A, et al:
Asymptomatic carriage of Pneumocystis jiroveci in subjects
undergoing bronchoscopy: a prospective study. Thorax. 58:594–597.
2003.PubMed/NCBI
|
|
29
|
Sing A, Roggenkamp A, Autenrieth IB and
Heesemann J: Pneumocystis carinii carriage in
immunocompetent patients with primary pulmonary disorders as
detected by single or nested PCR. J Clin Microbiol. 37:3409–3410.
1999.
|
|
30
|
Kaplan JE, Benson C, Holmes KH, Brooks JT,
Pau A and Masur H: Guidelines for prevention and treatment of
opportunistic infections in HIV-infected adults and adolescents:
recommendations from CDC, the National Institutes of Health, and
the HIV Medicine Association of the Infectious Diseases Society of
America. MMWR Recomm Rep. 58:1–207; quiz CE1–4. 2009.
|
|
31
|
Ripeau JS, Aumont F, Belhumeur P,
Ostrosky-Zeichner L, Rex JH and de Repentigny L: Effect of the
echinocandin caspofungin on expression of Candida albicans
secretory aspartyl proteinases and phospholipase in vitro.
Antimicrob Agents Chemother. 46:3096–3100. 2002.PubMed/NCBI
|
|
32
|
Deresinski SC and Stevens DA: Caspofungin.
Clin Infect Dis. 36:1445–1457. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Espinel-Ingroff A: Comparison of in vitro
activities of the new triazole SCH56592 and the echinocandins
MK-0991 (L-743,872) and LY303366 against opportunistic filamentous
and dimorphic fungi and yeasts. J Clin Microbiol. 36:2950–2956.
1998.PubMed/NCBI
|
|
34
|
Mu XD, Que CL, He B, Wang GF and Li HC:
Caspofungin in salvage treatment of severe Pneumocystis
pneumonia: case report and literature review. Chin Med J (Engl).
122:996–999. 2009.PubMed/NCBI
|
|
35
|
Zhang JC, Dai JY, Fan J and Wu XP: The
treatment of Pneumocystis carinii pneumonia with caspofungin
in elderly patients: a case report and literature review. Zhonghua
Jie He He Hu Xi Za Zhi. 29:463–465. 2006.(In Chinese).
|
|
36
|
Powles MA, Liberator P, Anderson J, et al:
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in
murine models of Pneumocystis carinii. Antimicrob Agents
Chemother. 42:1985–1989. 1998.PubMed/NCBI
|
|
37
|
Calderón EJ, Gutiérrez-Rivero S,
Durand-Joly I and Dei-Cas E: Pneumocystis infection in
humans: diagnosis and treatment. Expert Rev Anti Infect Ther.
8:683–701. 2010.PubMed/NCBI
|
|
38
|
Briel M, Boscacci R, Furrer H and Bucher
HC: Adjunctive corticosteroids for Pneumocystis jiroveci
pneumonia in patients with HIV infection: a meta-analysis of
randomised controlled trials. BMC Infect Dis. 5:1012005. View Article : Google Scholar
|
|
39
|
Pareja JG, Garland R and Koziel H: Use of
adjunctive corticosteroids in severe adult non-HIV Pneumocystis
carinii pneumonia. Chest. 113:1215–1224. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Delclaux C, Zahar JR, Amraoui G, et al:
Corticosteroids as adjunctive therapy for severe Pneumocystis
carinii pneumonia in non-human immunodeficiency virus-infected
patients: retrospective study of 31 patients. Clin Infect Dis.
29:670–672. 1999.PubMed/NCBI
|
|
41
|
Carmona EM and Limper AH: Update on the
diagnosis and treatment of Pneumocystis pneumonia. Ther Adv
Respir Dis. 5:41–59. 2011. View Article : Google Scholar
|
|
42
|
Lemiale V, Debrmetz A, Delannoy A, Alberti
C and Azoulay E: Adjunctive steroid in HIV-negative patients with
severe Pneumocystis pneumonia. Respir Res. 14:872013.
View Article : Google Scholar : PubMed/NCBI
|
